Anthropic Establishes Secret Wet Lab to Advance AI-Driven Biology and Drug Discovery
AI company Anthropic has established a physical wet lab in the San Francisco Bay Area to advance biological research and drug discovery, balancing rapid innovation with biosecurity concerns.
Anthropic has secretly established a physical wet lab in the San Francisco Bay Area to advance its research in drug discovery and biology, according to Eric Kauderer-Abrams, the company's head of life sciences. "We believe that to do biology, the ultimate test is, and will remain for some time, actual wet lab work," Kauderer-Abrams explained in a recent public interview, noting that the approach mirrors standard biotech practices.
Advancing Rare Disease Research via Robotics
This strategic step reflects Anthropic's ambition to target neglected diseases. The mission is deeply personal for CEO Dario Amodei, whose father passed away from an illness shortly before a cure was discovered. Kauderer-Abrams emphasized that life sciences represent the greatest opportunity for artificial intelligence to benefit humanity. To scale these efforts, Anthropic recently acquired the startup Coefficient Bio for approximately $400 million in stock and appointed Novartis CEO to its board of directors.
"We are in the very early stages of using artificial intelligence to automate laboratory work," said Eric Kauderer-Abrams, Head of Life Sciences at Anthropic.
Balancing Innovation and Biosecurity
Anthropic's push into physical laboratories comes amid internal tensions regarding safety. Some company researchers have warned that overly rapid development could pose existential risks, and Anthropic previously disclosed scenarios where its models could theoretically assist in biological weapons development. Despite CEO Dario Amodei calling for industry-wide slowdowns, the company continues to refine models to accelerate treatments while partnering with pharmaceutical giants such as Roche, Bristol Myers Squibb, and Novo Nordisk.
